<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">PYRIMETHAMINE</span><br/>(peer-i-meth'a-meen)<br/><span class="topboxtradename">Daraprim<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antimalarial</span><br/><b>Prototype: </b>Chloroquine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>25 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Long-acting folic acid antagonist chemically related to metabolite of chloroguanide. Selectively inhibits action of dehydrofolic
         reductate in parasites with resulting blockade of folic acid metabolism.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>No gametocidal activity but prevents development of fertilized gametes in the mosquito and thus helps to prevent transmission
         of malaria. Exhibits little value as single agent in treatment of acute primary malarial attack because action against blood-borne
         schizonts is slow in onset. Cross-resistance with chloroguanide may occur.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Prophylaxis of malaria due to susceptible strains of plasmodia. May be used conjointly with fast-acting antimalarial (e.g.,
         chloroquine, quinacrine, quinine) to initiate transmission control and suppressive cure. Used with a sulfonamide to provide
         synergistic action in treatment of toxoplasmosis.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Chloroguanide-resistant malaria; hypersensitivity to sulfonamides; megaloblastic anemia caused by folate deficiency; lactation;
         children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Patients with convulsive disorders receiving high doses of an anticonvulsant (e.g., phenytoin).</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Malaria Chemoprophylaxis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 25 mg once/wk<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> <i> 6.25 mg once/wk; <i>410 y,</i> 12.5 mg once/wk; <i>&gt;10 y,</i> 25 mg once/wk<br/><br/><span class="indicationtitle">Toxoplasmosis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 5075 mg/d with a sulfonamide for 13 wk, then decrease dose by half and continue for 1 mo<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 1 mg/kg/d divided into 2 doses with a sulfonamide for 13 wk, then decrease to 0.5 mg/kg/d for 1 mo (max: 25 mg/d)<br/></i></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Minimize GI distress by giving with meals. If symptoms persist, dosage reduction may be necessary.</li>
<li>Give on same day each week for malaria prophylaxis. Begin when individual enters malarious area and continue for 10 wk after
            leaving the area.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">GI:</span> Anorexia, vomiting, atrophic glossitis, abdominal cramps, diarrhea. <span class="typehead">Skin:</span> Skin rashes. <span class="typehead">Hematologic:</span> <span class="speceff-common">Folic acid deficiency</span> (<span class="speceff-common">megaloblastic anemia, leukopenia, thrombocytopenia, pancytopenia,</span> diarrhea). <span class="typehead">CNS:</span> CNS stimulation including convulsions, respiratory failure. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <b>Folic acid,</b> <b> <i>para</i> </b> <b>-aminobenzoic acid (PABA)</b> may decrease effectiveness against toxoplasmosis. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Peak:</span> 2 h. <span class="typehead">Distribution:</span> Concentrates in kidneys, lungs, liver, and spleen; distributed into breast milk. <span class="typehead">Elimination:</span> Excreted slowly in urine; excretion may extend over 30 d or longer. <span class="typehead">Half-Life:</span> 54148 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor patient response closely. Dosages required for treatment of toxoplasmosis approach toxic levels.</li>
<li>Lab tests: Perform blood counts, including platelets, twice weekly during therapy.</li>
<li>Withhold drug and notify physician if hematologic abnormalities appear.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Be aware that folic acid deficiency may occur with long-term use of pyrimethamine. Report to physician weakness, and pallor
            (from anemia), ulcerations of oral mucosa, superinfections, glossitis; GI disturbances such as diarrhea and poor fat absorption,
            fever. Folate (folinic acid) replacement may be prescribed. Increase food sources of folates (if allowed) in diet.
         </li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>